Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Equity Offering 11
Adamas Pharma Raises USD143.2 Million in Public Offering of Shares 11
Adamas Pharma Raises USD9.7 Million in Private Placement of Shares 13
Adamas Pharma Plans to Raise up to USD200 Million in Public Offering of Shares 14
Adamas Pharma Raises USD66 Million in Public Offering of Shares 15
Adamas Pharma Plans to Raise up to USD150 Million in Public Offering of Shares 17
Adamas Pharma Completes IPO For US$48 Million 18
Debt Offering 20
Adamas Pharma Raises USD35 Million in Private Placement of 11% Royalty-Backed Note Due 2026 20
Adamas Pharmaceuticals Inc – Key Competitors 21
Adamas Pharmaceuticals Inc – Key Employees 22
Adamas Pharmaceuticals Inc – Locations And Subsidiaries 23
Head Office 23
Recent Developments 24
Financial Announcements 24
Nov 02, 2018: Adamas reports third quarter 2018 financial results 24
Aug 02, 2018: Adamas announces second quarter 2018 financial results 26
May 03, 2018: Adamas Reports First Quarter 2018 Financial Results 27
Feb 22, 2018: Adamas Reports Recent Achievements and Financial Results for the Fourth Quarter and Full-Year 2017 28
Nov 02, 2017: Adamas Reports Recent Achievements and Third Quarter 2017 Financial Results 30
Aug 08, 2017: Adamas Reports Recent Achievements and Second Quarter 2017 Financial Results 32
May 09, 2017: Adamas Reports Recent Achievements and First Quarter 2017 Financial Results 34
Feb 28, 2017: Adamas Reports Recent Achievements and Financial Results for the Fourth Quarter and Full-Year 2016 35
Corporate Communications 37
Jun 28, 2017: Adamas Appoints New Chief Financial Officer 37
Apr 27, 2017: Adamas Pharmaceuticals appoints new COO 38
Product News 39
10/11/2017: Adamas Appoints Mardi C. Dier to its Board of Directors 39
09/13/2017: Adamas to Host Investor and Analyst Meeting on September 18, 2017 40
08/24/2017: Adamas Announces FDA Approval of GOCOVRI as First and Only Medication for the Treatment of Dyskinesia in Parkinson’s Disease Patients 41
05/24/2018: Adamas Announces Publication of Pharmacokinetic Data for GOCOVRI in Clinical Pharmacokinetics 42
04/27/2017: Adamas Appoints Richard A. King as Chief Operating Officer to Lead Commercialization of ADS-5102 43
04/12/2018: Adamas Announces Data Presentations on GOCOVRI at The American Academy Of Neurology Annual Meeting 44
01/08/2018: Adamas Announces U.S. Commercial Launch of GOCOVRI the First and Only FDA-approved Medication for the Treatment of Dyskinesia in Parkinsons Disease Patients 46
01/08/2017: Adamas Pharma Outlines Key Business Priorities for 2017, Provides Update on ADS-5102 47
01/08/2017: Adamas Pharmaceuticals Outlines Key Business Priorities for 2017, Provides Update on ADS-4101 48
Product Approvals 49
Oct 25, 2017: FDA Recognizes Orphan Drug Exclusivity for Adamas’ GOCOVRI 49
Jan 06, 2017: Adamas Announces U.S. FDA Acceptance of ADS-5102 New Drug Application for the Treatment of Levodopa-induced Dyskinesia in Patients with Parkinson’s Disease 50
Clinical Trials 51
Jun 22, 2018: Adamas Presents New Data Analysis Demonstrating that GOCOVRI Reduces Transitions between Dyskinesia and OFF Episodes Throughout the Day 51
Apr 19, 2018: Adamas Announces Final Results from the Two-Year Phase 3 Open-Label Study of GOCOVRI in Parkinson’s Disease Patients with Dyskinesia 52
Apr 12, 2018: Adamas Announces Data Presentations on ADS-4101 at The American Academy Of Neurology Annual Meeting 54
Apr 03, 2018: Adamas Announces First Patient Enrolled in Phase 3 Trial of ADS-5102 in Multiple Sclerosis Patients with Walking Impairment 55
Mar 15, 2018: Adamas Announces Publication of Data Supporting the Benefits of GOCOVRI in Parkinson Disease Patients with Dyskinesia 56
Feb 08, 2018: Adamas Announces Publication of Amantadine Immediate Release Subgroup Analysis From EASE LID 2 Open-label Study in Movement Disorders Clinical Practice 57
Feb 01, 2018: Adamas Announces Publication of ADS-5102 Phase 2 Clinical Trial Results in Multiple Sclerosis Journal 58
Sep 07, 2017: Adamas Announces Topline Phase 1b Data of ADS-4101 (lacosamide) for the Treatment of Partial Onset Seizures in Epilepsy 59
Jun 12, 2017: Adamas Announces Publication of ADS-5102 Phase 3 EASE LID Clinical Trial in JAMA Neurology 60
Jun 08, 2017: Adamas Presents Expanded Analysis from the ADS-5102 Open-Label Study Showing Tolerability and Durability out to 88 Weeks 62
May 22, 2017: Adamas Presents Positive Phase 1a Data of ADS-4101 (lacosamide) for the Treatment of Partial Onset Seizures in Epilepsy 64
Apr 24, 2017: Adamas Presents ADS-5102 Pooled Phase 3 Data Confirming Statistically Significant Reduction in Levodopa-Induced Dyskinesia and OFF Time in People with Parkinson’s Disease 66
Apr 18, 2017: Adamas Announces Oral and Poster Presentations of ADS-5102 Pooled Phase 3 Data at the 69th American Academy of Neurology Annual Meeting 68
Mar 28, 2017: Adamas Announces Data Presentation on ADS-5102 at the Academy of Managed Care Pharmacy 2017 Annual Meeting 69
Feb 28, 2017: Adamas Presents Additional Open-Label, Long-Term Safety and Efficacy Data on ADS-5102 at the First Pan American Parkinson’s Disease and Movement Disorders Congress 70
Feb 17, 2017: Adamas to Present New ADS-5102 Data from Phase 2 Trial in Walking Impairment Associated with Multiple Sclerosis at ACTRIMS Forum 2017 71
Jan 03, 2017: Adamas Pharmaceuticals Completes Phase 1 Clinical Trial of ADS-4101 for Treatment of Partial Onset Seizures in Patients with Epilepsy 72
Appendix 73
Methodology 73
About GlobalData 73
Contact Us 73
Disclaimer 73
Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Adamas Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Adamas Pharma Raises USD143.2 Million in Public Offering of Shares 11
Adamas Pharma Raises USD9.7 Million in Private Placement of Shares 13
Adamas Pharma Plans to Raise up to USD200 Million in Public Offering of Shares 14
Adamas Pharma Raises USD66 Million in Public Offering of Shares 15
Adamas Pharma Plans to Raise up to USD150 Million in Public Offering of Shares 17
Adamas Pharma Completes IPO For US$48 Million 18
Adamas Pharma Raises USD35 Million in Private Placement of 11% Royalty-Backed Note Due 2026 20
Adamas Pharmaceuticals Inc, Key Competitors 21
Adamas Pharmaceuticals Inc, Key Employees 22
List of Figures
Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
【免責事項】
http://www.globalresearch.jp/disclaimer